316 related articles for article (PubMed ID: 12667881)
1. Hormonal therapy: historical perspective to future directions.
Mcleod DG
Urology; 2003 Feb; 61(2 Suppl 1):3-7. PubMed ID: 12667881
[TBL] [Abstract][Full Text] [Related]
2. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
3. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
4. Hormonal therapy of prostate cancer.
Debruyne F
Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):4-9. PubMed ID: 12198632
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
Bayoumi AM; Brown AD; Garber AM
J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
[TBL] [Abstract][Full Text] [Related]
6. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.
Seidenfeld J; Samson DJ; Hasselblad V; Aronson N; Albertsen PC; Bennett CL; Wilt TJ
Ann Intern Med; 2000 Apr; 132(7):566-77. PubMed ID: 10744594
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
[TBL] [Abstract][Full Text] [Related]
8. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
Scherr DS; Pitts WR
J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
[TBL] [Abstract][Full Text] [Related]
9. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.
Marks LS
Urology; 2003 Dec; 62(6 Suppl 1):36-42. PubMed ID: 14706507
[TBL] [Abstract][Full Text] [Related]
10. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
11. Is the flare phenomenon clinically significant?
Bubley GJ
Urology; 2001 Aug; 58(2 Suppl 1):5-9. PubMed ID: 11502435
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in hormonal therapy for advanced prostate cancer.
Oottamasathien S; Crawford ED
Oncology (Williston Park); 2003 Aug; 17(8):1047-52; discussion 1054-8. PubMed ID: 12966672
[TBL] [Abstract][Full Text] [Related]
13. [Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer].
Fujikawa K; Awakura Y; Okabe T; Watanabe R; Nishimura S
Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):503-11; discussion 511-2. PubMed ID: 12795165
[TBL] [Abstract][Full Text] [Related]
14. Current topics and perspectives relating to hormone therapy for prostate cancer.
Suzuki H; Kamiya N; Imamoto T; Kawamura K; Yano M; Takano M; Utsumi T; Naya Y; Ichikawa T
Int J Clin Oncol; 2008 Oct; 13(5):401-10. PubMed ID: 18946750
[TBL] [Abstract][Full Text] [Related]
15. Hormonal therapy for stage D cancer of the prostate.
Gudziak MR; Smith AY
West J Med; 1994 Apr; 160(4):351-9. PubMed ID: 8023485
[TBL] [Abstract][Full Text] [Related]
16. Advanced prostate cancer. Hormonal treatment.
de la Haba-RodrÃguez J
Tunis Med; 2005 Dec; 83 Suppl 12():71-3. PubMed ID: 16430072
[No Abstract] [Full Text] [Related]
17. Hormonal therapy for locally advanced prostate cancer.
Einstein AB
NCI Monogr; 1988; (7):171-4. PubMed ID: 3050536
[TBL] [Abstract][Full Text] [Related]
18. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguere M; Borsanyi JP; Belanger A; Lacourciere Y; Emond J; Monfette G
J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
[TBL] [Abstract][Full Text] [Related]
19. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Hellerstedt B
Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
[TBL] [Abstract][Full Text] [Related]
20. Endocrine therapy for prostate cancer.
Damber JE
Acta Oncol; 2005; 44(6):605-9. PubMed ID: 16165920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]